Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Overview
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
Argenx SE
GeNeuro SA
Immupharma Plc
Momenta Pharmaceuticals Inc
Octapharma AG
Pfizer Inc
Takeda Pharmaceutical Co Ltd
UCB SA
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Drug Profiles
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronidase (recombint, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Dormant Projects
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Discontinued Products
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Product Development Milestones
Featured News & Press Releases
May 18, 2020: Fil results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyeliting polyneuropathy (CIDP) presented at AAN 2020
Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045
Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Desigtion From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Momenta Pharmaceuticals Inc, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2020
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, H2 2020